Cargando…

Physiologic and Pharmacologic Modulation of Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Expression in β-Cells by Peroxisome Proliferator–Activated Receptor (PPAR)-γ Signaling: Possible Mechanism for the GIP Resistance in Type 2 Diabetes

OBJECTIVE: We previously showed that peroxisome proliferator–activated receptor (PPAR)-γ in β-cells regulates pdx-1 transcription through a functional PPAR response element (PPRE). Gene Bank blast for a homologous nucleotide sequence revealed the same PPRE within the rat glucose-dependent insulinotr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Dhananjay, Peshavaria, Mina, Monga, Navjot, Jetton, Thomas L., Leahy, Jack L.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874705/ https://www.ncbi.nlm.nih.gov/pubmed/20332343 http://dx.doi.org/10.2337/db09-1655

Ejemplares similares

Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women
por: Garg, Gaurav, et al.
Publicado: (2015)

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
por: Bulum, Tomislav
Publicado: (2022)

Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly
por: Shekhawat, Vikram Singh, et al.
Publicado: (2019)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

Investigation of endothelial nitric oxide (NO) signalling in response to the incretin hormone glucose-dependent insulinotropic polypeptide (GIP)
por: Savage, PJ, et al.
Publicado: (2012)

The effect of glucose-dependent insulinotropic polypeptide (GIP) variants on visceral fat accumulation in Han Chinese populations
por: Wang, T, et al.
Publicado: (2017)

N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor
por: Hansen, L S, et al.
Publicado: (2016)

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
por: Zhang, Qian, et al.
Publicado: (2021)

Administration of Jerusalem artichoke reduces the postprandial plasma glucose and glucose-dependent insulinotropic polypeptide (GIP) concentrations in humans
por: Takahashi, Hirokazu, et al.
Publicado: (2022)

GIP_HUMAN [22–51] Peptide Encoded by the Glucose-Dependent Insulinotropic Polypeptide (GIP) Gene Suppresses Insulin Expression and Secretion in INS-1E Cells and Rat Pancreatic Islets
por: Pusch, Emily, et al.
Publicado: (2023)

Over-expression, purification and isotopic labeling of a tag-less human glucose-dependent insulinotropic polypeptide (hGIP)
por: Chandarana, Rakesh C., et al.
Publicado: (2013)

Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted rats
por: Lee, Tsung-Ming, et al.
Publicado: (2016)

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
por: Sparre‐Ulrich, A H, et al.
Publicado: (2015)

Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice
por: Shimazu-Kuwahara, Satoko, et al.
Publicado: (2017)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Fisman, Enrique Z., et al.
Publicado: (2021)

Imaging of the Glucose-Dependent Insulinotropic Polypeptide Receptor Using a Novel Radiolabeled Peptide Rationally Designed Based on Endogenous GIP and Synthetic Exendin-4 Sequences
por: Velikyan, Irina, et al.
Publicado: (2022)

Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the GIPR Region
por: Bowker, Nicholas, et al.
Publicado: (2021)

Ethnic disparities in insulin and glucose-dependent insulinotropic peptide (GIP) responses to intraduodenal glucose in health
por: Marathe, Chinmay S., et al.
Publicado: (2014)

The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
por: Fukuda, Makoto
Publicado: (2021)

Marked Cortisol Production by Intracrine ACTH in GIP-Treated Cultured Adrenal Cells in Which the GIP Receptor Was Exogenously Introduced
por: Fujii, Hiroko, et al.
Publicado: (2014)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

GIP1 and GIP2 Contribute to the Maintenance of Genome Stability at the Nuclear Periphery
por: Singh, Gaurav, et al.
Publicado: (2022)

Physiological roles of the GIP receptor in murine brown adipose tissue
por: Beaudry, Jacqueline L., et al.
Publicado: (2019)

GIP receptor agonism blocks chemotherapy-induced nausea and vomiting
por: Borner, Tito, et al.
Publicado: (2023)

Serum Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in association with the Risk of Gestational Diabetes: A Prospective Case-Control Study
por: Mosavat, Maryam, et al.
Publicado: (2020)

Mechanism of Cancer Growth Suppression of Alpha-Fetoprotein Derived Growth Inhibitory Peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects
por: Mizejewski, Gerald J.
Publicado: (2011)

Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long‐term impairment of the GIP system
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2019)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
por: Pelle, Maria Chiara, et al.
Publicado: (2021)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
por: Zhao, Fenghui, et al.
Publicado: (2022)

Vaccination against GIP for the Treatment of Obesity
por: Fulurija, Alma, et al.
Publicado: (2008)

The Effect of Cell Surface Expression and Linker Sequence on the Recruitment of Arrestin to the GIP Receptor
por: Al-Sabah, Suleiman, et al.
Publicado: (2020)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
por: Ludwig, Mette Q., et al.
Publicado: (2021)

Regulation of GIP and GLP1 Receptor Cell Surface Expression by N-Glycosylation and Receptor Heteromerization
por: Whitaker, Gina M., et al.
Publicado: (2012)

ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the incretin polypeptide GIP
por: Vidal, Oscar M., et al.
Publicado: (2022)

The effect of gastrointestinal pathogen panel (GIP) on antibiotic management
por: Saling, Christopher F., et al.
Publicado: (2021)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
por: Jonik, Szymon, et al.
Publicado: (2022)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_87clh105p8p9vijfj6auu3gl1d